ArticleJournal of molecular modeling2026
In Silico Discovery of mTOR Inhibitors as Potential Therapeutics for Feline Hypertrophic Cardiomyopathy.
Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextFeline Hypertrophic Cardiomyopathy (HCM) is a significant health issue, with a current prevalence of 14.7% in cats. The mammalian target of rapamycin (mTOR) is an atypical serine/threonine protein kinase system that also participates in the control of structural and functional remodeling of the heart in relation to haemodynamic stress and non-hemodynamic stimuli. Here, we sought to discover candidate feline-specific inhibitors of mTOR for the treatment of HCM using an integrated computational pipeline combining homology modeling, virtual screening, and molecular dynamics simulations. Using this pipeline, we screened the DrugBank database and identified 17 candidate compounds that bind significantly better than rapamycin, serving as a control mTOR inhibitor. Both molecular dynamics (MD) simulation and MM/PBSA calculations indicated that the screened compound, dihydro-alpha-ergocryptine, exhibited a higher binding affinity and stability with feline mTOR compared to rapamycin. Moreover, ADMET analysis further demonstrated that the compound had good drug-like properties.
methodsHomologous models of feline mTOR were built using publicly available software MODELLER (version 10.5) and the SWISS-MODEL webserver. Homologous templates were used to predict the active binding sites. Structure-based virtual screening of high-affinity small molecule compounds from the DrugBank database was carried out using AutoDock Vina (version 1.2.0). Molecular dynamics (MD) simulations were performed using the GROMACS software version 2021.4. The CHARMM36 all-atom force field parameterised the protein, and the ligand's parameters were taken from the GAFF force field. The simulations were equilibrated under NVT and NPT conditions. During trajectory analysis (RMSD, RMSF, radius of gyration, SASA and hydrogen bonding), the complex stability was evaluated to identify the best potential mTOR inhibitor candidates using OriginPro (version 2024).
Indexed as
Identifiers
42371166What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.